Access | VITRAKVI® (larotrectinib)

Patient support for all aspects of their
treatment journey

Learn about TRAK Assist™, a patient assistance program for all aspects of the treatment journey.
TRAK Assist provides several options to help patients access their VITRAKVI® treatment
  • TRAK Assist $0 Co-Pay Program for VITRAKVI for eligible patients with commercial or private insurancea
  • VITRAKVI Bridge Program for commercially insured patients whose coverage is delayed or who experience a temporary lapse in coverage
    • Provides free VITRAKVI for a limited period of time while a patient is without coverage
  • Referrals to independent assistance foundations for publicly insured patients who need help with out-of-pocket costs related to their treatmentb
  • Bayer US Patient Assistance Foundation for qualified uninsured or underinsured patients
Comprehensive and coordinated support for patients
  • A dedicated phone line provides patients taking VITRAKVI direct access to a nurse or pharmacist who can answer questions about treatment with VITRAKVI
  • Regularly scheduled outbound calls to provide information about VITRAKVI treatment
  • TRAK Assist may also be able to provide resources that can help patients get access to NTRK* gene fusion diagnostic testing. It's important to note that patients will need to undergo NTRK gene fusion diagnostic testing to determine whether they are candidates for VITRAKVI
VITRAKVI Commitment Program
  • Bayer will provide full or partial refunds (for up to 60 days) to patients (through the Bayer In-Network Specialty Pharmacy) for patients who do not receive clinical benefitc within 90 days of initiation on VITRAKVI (program rules apply)

Help connecting with a Bayer In-Network Specialty Pharmacy

Accredo®: 1-855-540-1797; www.accredo.com

CVS Specialty Pharmacy: 1-800-790-1698; www.cvsspecialty.com

US Bioservices: 1-833-230-1407; www.usbioservices.com

*NTRK, neurotrophic receptor tyrosine kinase. aPatients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the co-payment support provided under this program, e.g., co-pay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payers of any benefits they receive and the value of this program, as required by contract or otherwise. Void where prohibited by law, taxed, or restricted. Patients enrolled in the Bayer Patient Assistance Foundation are not eligible. Company may determine eligibility, monitor participation, equitably distribute product and modify or discontinue any aspect of TRAK Assist $0 Co-Pay Program for VITRAKVI at any time, including but not limited to this commercial co-pay assistance program. bTRAK Assist offers referrals to third-party assistance programs; eligibility criteria apply. cClinical benefit is defined at the discretion of the physician, and does not require any confirmatory documentation by the physician. Discontinuation solely due to adverse events does not qualify patients for the VITRAKVI Commitment Program.

To learn more about support through TRAK Assist, call 1-844-634-TRAK
(1-844-634-8725).

See the Interactive PI See the Interactive PI

Indication

VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that:

  • have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
  • are metastatic or where surgical resection is likely to result in severe morbidity, and
  • have no satisfactory alternative treatments or that have progressed following treatment.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Important Safety Information

Neurotoxicity: Among the 176 patients who received VITRAKVI, neurologic adverse reactions of any grade occurred in 53% of patients, including Grade 3 and Grade 4 neurologic adverse reactions in 6% and 0.6% of patients, respectively. The majority (65%) of neurologic adverse reactions occurred within the first three months of treatment (range 1 day to 2.2 years). Grade 3 neurologic adverse reactions included delirium (2%), dysarthria (1%), dizziness (1%), gait disturbance (1%), and paresthesia (1%). Grade 4 encephalopathy (0.6%) occurred in a single patient. Neurologic adverse reactions leading to dose modification included dizziness (3%), gait disturbance (1%), delirium (1%), memory impairment (1%), and tremor (1%).

Advise patients and caretakers of these risks with VITRAKVI. Advise patients not to drive or operate hazardous machinery if they are experiencing neurologic adverse reactions. Withhold or permanently discontinue VITRAKVI based on the severity. If withheld, modify the VITRAKVI dose when resumed.

Hepatotoxicity: Among the 176 patients who received VITRAKVI, increased transaminases of any grade occurred in 45%, including Grade 3 increased AST or ALT in 6% of patients. One patient (0.6%) experienced Grade 4 increased ALT. The median time to onset of increased AST was 2 months (range: 1 month to 2.6 years). The median time to onset of increased ALT was 2 months (range: 1 month to 1.1 years). Increased AST and ALT leading to dose modifications occurred in 4% and 6% of patients, respectively. Increased AST or ALT led to permanent discontinuation in 2% of patients.

Monitor liver tests, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated. Withhold or permanently discontinue VITRAKVI based on the severity. If withheld, modify the VITRAKVI dosage when resumed.

Embryo-Fetal Toxicity: VITRAKVI can cause fetal harm when administered to a pregnant woman. Larotrectinib resulted in malformations in rats and rabbits at maternal exposures that were approximately 11- and 0.7-times, respectively, those observed at the clinical dose of 100 mg twice daily.

Advise women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment and for 1 week after the final dose of VITRAKVI.

Most Common Adverse Reactions (≥20%): The most common adverse reactions (≥20%) were: increased ALT (45%), increased AST (45%), anemia (42%), fatigue (37%), nausea (29%), dizziness (28%), cough (26%), vomiting (26%), constipation (23%), and diarrhea (22%).

Drug Interactions: Avoid coadministration of VITRAKVI with strong CYP3A4 inhibitors (including grapefruit or grapefruit juice), strong CYP3A4 inducers (including St. John’s wort), or sensitive CYP3A4 substrates. If coadministration of strong CYP3A4 inhibitors or inducers cannot be avoided, modify the VITRAKVI dose as recommended. If coadministration of sensitive CYP3A4 substrates cannot be avoided, monitor patients for increased adverse reactions of these drugs.

Lactation: Advise women not to breastfeed during treatment with VITRAKVI and for 1 week after the final dose.

For important risk and use information about VITRAKVI, please see the full Prescribing Information.

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
For Bayer products you can report these directly to Bayer by clicking here.

Reference:

  • 1. VITRAKVI [package insert]. Stamford, CT: Loxo Oncology, Inc.; November 2018.

Attention

You are now leaving the VITRAKVI.com website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.

Thank you for visiting VITRAKVI.com.

Attention

You are now leaving the VITRAKVI.com website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.

Thank you for visiting VITRAKVI.com.

Attention

The information provided in this section is intended
expressly for healthcare professionals in the United States.
Click “OK” to enter if you are a US healthcare professional.

Attention

You are now leaving the VITRAKVI.com website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.

Thank you for visiting VITRAKVI.com.

Attention

You are now leaving the VITRAKVI.com website.
Bayer is not responsible for the content presented by any independent website, including any advertising claims, special offers, illustrations, names, or endorsements.

Thank you for visiting VITRAKVI.com.